{"id":"arsenic-trioxide-injectable-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Differentiation syndrome (APL differentiation syndrome)"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hyperleukocytosis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Arsenic trioxide targets the PML-RARA fusion protein characteristic of APL, causing its degradation and leading to differentiation of leukemic promyelocytes into mature granulocytes. It also triggers apoptosis through mitochondrial pathways and generation of reactive oxygen species. The drug has dual activity as both a differentiating agent and an apoptosis inducer, making it effective in APL and potentially other hematologic malignancies.","oneSentence":"Arsenic trioxide induces differentiation and apoptosis in leukemic cells, particularly in acute promyelocytic leukemia (APL), through multiple pathways including PML-RARA protein degradation and reactive oxygen species generation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:21.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute promyelocytic leukemia (APL)"},{"name":"Relapsed or refractory APL"}]},"trialDetails":[{"nctId":"NCT03980665","phase":"PHASE1","title":"The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART","status":"UNKNOWN","sponsor":"Guangzhou 8th People's Hospital","startDate":"2019-04-01","conditions":"HIV/AIDS","enrollment":20},{"nctId":"NCT02966301","phase":"PHASE2","title":"Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide","status":"COMPLETED","sponsor":"Medsenic","startDate":"2016-12","conditions":"Chronic Graft-Versus-Host Disease, Immune System Diseases","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trisenox / Arscimed"],"phase":"phase_2","status":"active","brandName":"Arsenic Trioxide Injectable Solution","genericName":"Arsenic Trioxide Injectable Solution","companyName":"Medsenic","companyId":"medsenic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Arsenic trioxide induces differentiation and apoptosis in leukemic cells, particularly in acute promyelocytic leukemia (APL), through multiple pathways including PML-RARA protein degradation and reactive oxygen species generation. Used for Acute promyelocytic leukemia (APL), Relapsed or refractory APL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}